​

Insmed (INSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INSM Stock Forecast

Insmed (INSM) stock forecast, based on 34 Wall Street analysts, predicts a 12-month average price target of $214.47, with a high of $269.00 and a low of $166.00. This represents a 53.72% increase from the last price of $139.52.

- $60 $120 $180 $240 $300 High: $269 Avg: $214.47 Low: $166 Last Closed Price: $139.52

INSM Stock Rating

Insmed stock's rating consensus is Buy, based on 34 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (91.18%), 2 Hold (5.88%), 1 Sell (2.94%), and 0 Strong Sell (0.00%).

Buy
Total 34 1 2 31 Strong Sell Sell Hold Buy Strong Buy

INSM Price Target Upside V Benchmarks

TypeNameUpside
StockInsmed53.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts52234
Avg Price Target$198.80$206.55$209.24
Last Closing Price$139.52$139.52$139.52
Upside/Downside42.49%48.04%49.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 262171--20
Feb, 262181--21
Jan, 261171--19
Dec, 251161--18
Nov, 253151--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Mizuho Securities$204.00$159.0328.28%46.22%
Feb 20, 2026Morgan Stanley$166.00$158.804.53%18.98%
Feb 20, 2026Tiago FauthWells Fargo$208.00$161.0029.19%49.08%
Feb 19, 2026Stifel Nicolaus$205.00$159.8828.22%46.93%
Feb 19, 2026Graig SuvannavejhMizuho Securities$211.00$151.1139.63%51.23%
Jan 27, 2026Eliana MerleBarclays$231.00$162.6442.03%65.57%
Jan 22, 2026Roth Capital$212.00$160.3932.18%51.95%
Jan 21, 2026Leonid TimashevRBC Capital$200.00$163.5122.32%43.35%
Jan 12, 2026Danielle BrillTruist Financial$205.00$166.2623.30%46.93%
Jan 08, 2026Maxwell SkorMorgan Stanley$157.00$176.00-10.80%12.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 20, 2026Wells FargoOverweightOverweighthold
Jan 27, 2026BarclaysOverweightOverweightinitialise
Jan 22, 2026Roth CapitalBuyinitialise
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 06, 2026UBSBuyBuyhold
Dec 18, 2025RBC CapitalOutperformOutperformhold
Dec 18, 2025CitigroupOutperformOutperformhold
Dec 18, 2025Wolfe ResearchOutperformOutperformhold
Dec 16, 2025Wells FargoOverweightOverweighthold
Dec 16, 2025Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.88$-3.91$-5.34$-5.57$-6.42---
Avg Forecast$-3.82$-3.72$-5.21$-5.36$-4.35$-2.65$0.86$4.09
High Forecast$-3.26$-3.04$-5.10$-5.21$-3.10$-0.94$4.06$5.65
Low Forecast$-4.43$-4.82$-5.34$-5.57$-5.38$-4.65$-0.81$3.23
Surprise %1.57%5.11%2.50%3.92%47.59%---

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$188.46M$245.36M$305.21M$363.71M$606.42M---
Avg Forecast$179.85M$247.85M$303.42M$357.89M$506.74M$1.03B$1.94B$2.87B
High Forecast$202.16M$304.60M$392.20M$364.25M$660.57M$1.04B$2.51B$3.71B
Low Forecast$159.62M$213.35M$303.41M$351.53M$414.94M$1.02B$1.63B$2.40B
Surprise %4.79%-1.00%0.59%1.62%19.67%---

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-434.65M$-481.53M$-749.57M$-913.77M$-1.28B---
Avg Forecast$-400.47M$-434.01M$-749.57M$-757.05M$-595.36M$-478.57M$157.64M$574.37M
High Forecast$-320.37M$-347.20M$-599.65M$-732.14M$-435.02M$-131.70M$570.16M$792.86M
Low Forecast$-480.56M$-520.81M$-899.48M$-781.97M$-755.70M$-652.68M$-113.75M$453.50M
Surprise %8.54%10.95%-20.70%114.45%---

INSM Forecast FAQ

Is Insmed stock a buy?

Insmed stock has a consensus rating of Buy, based on 34 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Insmed is a favorable investment for most analysts.

What is Insmed's price target?

Insmed's price target, set by 34 Wall Street analysts, averages $214.47 over the next 12 months. The price target range spans from $166 at the low end to $269 at the high end, suggesting a potential 53.72% change from the previous closing price of $139.52.

How does Insmed stock forecast compare to its benchmarks?

Insmed's stock forecast shows a 53.72% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Insmed over the past three months?

  • March 2026: 10.00% Strong Buy, 85.00% Buy, 5.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 9.52% Strong Buy, 85.71% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 5.26% Strong Buy, 89.47% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.

What is Insmed’s EPS forecast?

Insmed's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.65, marking a -58.72% decrease from the reported $-6.42 in 2025. Estimates for the following years are $0.86 in 2027, and $4.09 in 2028.

What is Insmed’s revenue forecast?

Insmed's average annual revenue forecast for its fiscal year ending in December 2026 is $1.03B, reflecting a 70.20% increase from the reported $606.42M in 2025. The forecast for 2027 is $1.94B, and $2.87B for 2028.

What is Insmed’s net income forecast?

Insmed's net income forecast for the fiscal year ending in December 2026 stands at $-479M, representing a -62.52% decrease from the reported $-1.277B in 2025. Projections indicate $157.64M in 2027, and $574.37M in 2028.